All In Biotech

NDA 211635 · Neurelis INC

Valtoco

Diazepam · Nasal · Benzodiazepine

Orphan

Last checked: Nov 19, 2026Latest source record: Jun 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jan 10, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

118

16 Phase 3, 6 recruiting

FAERS reports

90,834

77,085 serious, 20,903 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) and Drug Interactions (7.1) ] . The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes....

What it is approved for

From the label in effect Jun 3, 2026.

VALTOCO ® is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2 years of age and older. VALTOCO is a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2 years of age and older. ( 1 )

Mechanism: The exact mechanism of action for diazepam is not fully understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA A receptor.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • VALTOCO · DIAZEPAM 7.5MG/SPRAY · SPRAY, NASAL · Prescription
  • VALTOCO · DIAZEPAM 10MG/SPRAY · SPRAY, NASAL · Prescription
  • VALTOCO · DIAZEPAM 5MG/SPRAY · SPRAY, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Diazepam" as an intervention, any sponsor and status, largest first.

All 118 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • toxicity to various agents9,224
  • drug abuse6,198
  • drug ineffective5,161
  • nausea4,223
  • drug interaction3,890
  • completed suicide3,880
  • fatigue3,865
  • somnolence3,697
  • off label use3,647
  • death3,415
  • anxiety3,398
  • headache3,292

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,140
20051,344
20061,170
20071,233
20081,797
20091,793
20102,345
20112,776
20123,252
20133,740
20143,766
20154,657
20165,306
20175,529
20186,524
20197,146
20206,752
20215,754
20225,062
20234,948
20245,314
20255,358
20264,117

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Valtoco (Diazepam)

2024 spending

$24.4M

Beneficiaries

9,366

20,987 claims

Per beneficiary

$2,604

$354.13 per unit

View as table
YearSpending
2020$1,303,028
2021$5,591,384
2022$10,355,205
2023$17,228,355
2024$24,386,030

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,534 on PubMed

Sponsor: Neurelis INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.